Key Inclusion Criteria:

          -  Histologically or cytologically confirmed locally advanced or metastatic malignant
             solid tumor that is refractory to or intolerant of standard therapy or for which no
             standard therapy is available

          -  Have measurable disease on imaging based on Response Evaluation Criteria in Solid
             Tumors Version 1.1 (RECIST 1.1)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

          -  Life expectancy of ≥ 3 months, in the opinion of the investigator

          -  Adequate organ function as assessed by hematological, renal, and hepatic parameters,
             and no clinically significant coagulopathy

        Key Exclusion Criteria:

          -  Received prior systemic cytotoxic chemotherapy, biological therapy, radiotherapy, or
             major surgery within 3 weeks of Cycle 1 Day 1; a 1-week washout is permitted for
             palliative radiation to non-central nervous system (CNS) disease with sponsor approval

          -  Known severe hypersensitivity reactions (NCI CTCAE Grade ≥ 3) to fully human
             monoclonal antibodies or fusion proteins, GS-3583 formulation excipients, or severe
             reaction to immuno-oncology agents, such as colitis or pneumonitis requiring treatment
             with corticosteroids, any history of anaphylaxis, or uncontrolled asthma

          -  Concurrent active malignancy other than nonmelanoma skin cancer, carcinoma in situ of
             the cervix, or superficial bladder cancer who has undergone potentially curative
             therapy with no evidence of disease. Individuals with other previous malignancies are
             eligible if disease free for > 2 years.

          -  Previous history of hematological malignancy, monoclonal gammopathy of unknown
             significance (MGUS) or other preleukemic states (Presence of clonal hematopoiesis of
             indeterminate potential (CHIP)/age related clonal hematopoiesis (ARCH) is acceptable)

          -  Known CNS metastasis(es), unless metastases are treated and stable and the individual
             does not require systemic corticosteroids for management of CNS symptoms at least 1
             week prior to study treatment. Individuals with history of carcinomatous meningitis
             are excluded regardless of clinical stability.

          -  Active or history of autoimmune disease that has required systemic treatment within 2
             years of the start of study treatment (ie, with use of disease-modifying agents,
             corticosteroids, or immunosuppressive drugs)

               -  Note: Individuals with diabetes type 1, vitiligo, psoriasis, hypothyroid disease,
                  or hyperthyroid disease, not requiring immunosuppressive treatment are eligible.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.